{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T23:03:07Z","timestamp":1789945387705,"version":"4.0.1"},"reference-count":131,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Cooperative Research Thematic Network","award":["RD12\/0036\/0058"],"award-info":[{"award-number":["RD12\/0036\/0058"]}]},{"name":"Red de Cancer","award":["RD12\/0036\/0046"],"award-info":[{"award-number":["RD12\/0036\/0046"]}]},{"name":"Instituto de Salud Carlos III, Spain"},{"name":"Instituto de Salud Carlos III\/Subdirecci\u00f3n General de Investigaci\u00f3n Sanitaria","award":["PI060339"],"award-info":[{"award-number":["PI060339"]}]},{"name":"Instituto de Salud Carlos III\/Subdirecci\u00f3n General de Investigaci\u00f3n Sanitaria","award":["06\/1354"],"award-info":[{"award-number":["06\/1354"]}]},{"name":"Instituto de Salud Carlos III\/Subdirecci\u00f3n General de Investigaci\u00f3n Sanitaria","award":["02\/0905"],"award-info":[{"award-number":["02\/0905"]}]},{"name":"Instituto de Salud Carlos III\/Subdirecci\u00f3n General de Investigaci\u00f3n Sanitaria","award":["01\/0089\/01-02"],"award-info":[{"award-number":["01\/0089\/01-02"]}]},{"name":"Instituto de Salud Carlos III\/Subdirecci\u00f3n General de Investigaci\u00f3n Sanitaria","award":["PI12\/01293"],"award-info":[{"award-number":["PI12\/01293"]}]},{"name":"Instituto de Salud Carlos III\/Subdirecci\u00f3n General de Investigaci\u00f3n Sanitaria","award":["PS09\/01"],"award-info":[{"award-number":["PS09\/01"]}]},{"name":"Instituto de Salud Carlos III\/Subdirecci\u00f3n General de Investigaci\u00f3n Sanitaria","award":["PS09\/01897\/01370"],"award-info":[{"award-number":["PS09\/01897\/01370"]}]},{"name":"Instituto de Salud Carlos III\/Subdirecci\u00f3n General de Investigaci\u00f3n Sanitaria","award":["G03\/136"],"award-info":[{"award-number":["G03\/136"]}]},{"DOI":"10.13039\/501100002704","name":"Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["GCB120981SAN"],"award-info":[{"award-number":["GCB120981SAN"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","bloodreviews.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.blre.2015.06.001","type":"journal-article","created":{"date-parts":[[2015,6,14]],"date-time":"2015-06-14T06:25:52Z","timestamp":1434263152000},"page":"387-403","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Treatment for patients with newly diagnosed multiple myeloma in 2015"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2390-1218","authenticated-orcid":false,"given":"Mar\u00eda-Victoria","family":"Mateos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique M.","family":"Ocio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Paiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Rosi\u00f1ol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Mart\u00ednez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Blad\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan-Jos\u00e9","family":"Lahuerta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram\u00f3n","family":"Garc\u00eda-Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas F.","family":"San Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.blre.2015.06.001_bb0005","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Multiple myeloma","volume":"351","author":"Kyle","year":"2004","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.blre.2015.06.001_bb0010","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/leu.2012.259","article-title":"Treatment patterns and outcomes in elderly patients with multiple myeloma","volume":"27","author":"Bang","year":"2013","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.blre.2015.06.001_bb0015","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.blre.2015.06.001_bb0020","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1182\/blood-2012-02-408922","article-title":"Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA\/GEM study","volume":"120","author":"Rosinol","year":"2012","journal-title":"Blood"},{"issue":"9758","key":"10.1016\/j.blre.2015.06.001_bb0025","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","volume":"376","author":"Cavo","year":"2010","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.blre.2015.06.001_bb0030","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.blre.2015.06.001_bb0035","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1182\/blood-2011-03-341669","article-title":"Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials","volume":"118","author":"Fayers","year":"2011","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.blre.2015.06.001_bb0040","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2015.06.001_bb0045","series-title":"Prolonged overall survival with lenalidomide plus dexamethasone compared with dexamethasone alone in patients with relapsed or refractory multiple myeloma","first-page":"412","volume":"110","author":"Weber","year":"2007"},{"issue":"10","key":"10.1016\/j.blre.2015.06.001_bb0050","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1038\/leu.2013.166","article-title":"A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control","volume":"27","author":"Paiva","year":"2013","journal-title":"Leukemia"},{"issue":"36","key":"10.1016\/j.blre.2015.06.001_bb0055","doi-asserted-by":"crossref","first-page":"4529","DOI":"10.1200\/JCO.2013.49.0086","article-title":"Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma","volume":"31","author":"Kapoor","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.blre.2015.06.001_bb0060","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/blood-2011-07-370460","article-title":"High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma","volume":"119","author":"Paiva","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2015.06.001_bb0065","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/cncr.23546","article-title":"Complete remission sustained 3years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma","volume":"113","author":"Barlogie","year":"2008","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.blre.2015.06.001_bb0070","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/bjh.12576","article-title":"Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results from a GEM\/PETHEMA study","volume":"163","author":"Martinez-Lopez","year":"2013","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.blre.2015.06.001_bb0075","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","article-title":"Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT European Group for Blood and Marrow Transplant","volume":"102","author":"Blade","year":"1998","journal-title":"Br J Haematol"},{"issue":"18","key":"10.1016\/j.blre.2015.06.001_bb0080","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1","volume":"117","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.blre.2015.06.001_bb0085","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.3324\/haematol.2012.065359","article-title":"Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma","volume":"97","author":"Hillengass","year":"2012","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.blre.2015.06.001_bb0090","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2009-03-213280","article-title":"F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma","volume":"114","author":"Bartel","year":"2009","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2015.06.001_bb0095","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/bjh.12007","article-title":"The role of imaging techniques in the management of multiple myeloma","volume":"159","author":"Zamagni","year":"2012","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.blre.2015.06.001_bb0100","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1182\/blood-2012-08-451690","article-title":"Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3","volume":"121","author":"Usmani","year":"2013","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.blre.2015.06.001_bb0105","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1182\/blood-2011-06-361386","article-title":"Prognostic relevance of 18-F FDG PET\/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation","volume":"118","author":"Zamagni","year":"2011","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.blre.2015.06.001_bb0110","doi-asserted-by":"crossref","first-page":"5984","DOI":"10.1182\/blood-2011-09-379818","article-title":"PET-CT in MM: a new definition of CR","volume":"118","author":"Moreau","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2015.06.001_bb0115","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/leu.2012.197","article-title":"Immunoglobulin heavy\/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients","volume":"27","author":"Ludwig","year":"2013","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.blre.2015.06.001_bb0120","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1182\/blood-2009-01-198788","article-title":"The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma","volume":"114","author":"Chee","year":"2009","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2015.06.001_bb0125","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2008-05-159624","article-title":"Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation","volume":"112","author":"Paiva","year":"2008","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.blre.2015.06.001_bb0130","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1200\/JCO.2012.46.2119","article-title":"Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study","volume":"31","author":"Rawstron","year":"2013","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.blre.2015.06.001_bb0135","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1182\/blood-2014-05-573733","article-title":"GEM2005 trial update comparing VMP\/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?","volume":"124","author":"Mateos","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2015.06.001_bb0140","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1182\/blood-2013-05-506170","article-title":"Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity","volume":"122","author":"Flanders","year":"2013","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2015.06.001_bb0145","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1038\/leu.2012.120","article-title":"EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes","volume":"26","author":"van Dongen","year":"2012","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.blre.2015.06.001_bb0150","first-page":"1365","article-title":"Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry","volume":"90","author":"Sarasquete","year":"2005","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.blre.2015.06.001_bb0155","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.leukres.2005.01.017","article-title":"Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation","volume":"29","author":"Galimberti","year":"2005","journal-title":"Leuk Res"},{"issue":"2","key":"10.1016\/j.blre.2015.06.001_bb0160","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/leu.2013.217","article-title":"Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry","volume":"28","author":"Puig","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2015.06.001_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2011.07.002","article-title":"The level of minimal residual disease in the bone marrow of patients with multiple myeloma before high-dose therapy and autologous blood stem cell transplantation is an independent predictive parameter","volume":"18","author":"Korthals","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2015.06.001_bb0170","article-title":"Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders","author":"Ladetto","year":"2013","journal-title":"Leukemia"},{"issue":"20","key":"10.1016\/j.blre.2015.06.001_bb0175","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1182\/blood-2014-01-550020","article-title":"Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma","volume":"123","author":"Martinez-Lopez","year":"2014","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.blre.2015.06.001_bb0180","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1182\/blood-2009-08-238196","article-title":"Hematopoietic stem cell transplantation for multiple myeloma beyond 2010","volume":"115","author":"Blade","year":"2010","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2015.06.001_bb0185","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/sj.bmt.1703035","article-title":"Impact of complete remission with intensive therapy in patients with responsive multiple myeloma","volume":"27","author":"Alexanian","year":"2001","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.blre.2015.06.001_bb0190","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1586\/17474086.2014.871200","article-title":"Initial treatment of transplant-eligible patients in multiple myeloma","volume":"7","author":"Rosinol","year":"2014","journal-title":"Expert Rev Hematol"},{"issue":"11","key":"10.1016\/j.blre.2015.06.001_bb0195","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1182\/blood-2010-08-300863","article-title":"Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial","volume":"117","author":"Moreau","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2015.06.001_bb0200","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1182\/blood-2005-02-0522","article-title":"Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma","volume":"106","author":"Cavo","year":"2005","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2015.06.001_bb0205","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J Clin Oncol"},{"issue":"30","key":"10.1016\/j.blre.2015.06.001_bb0210","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1200\/JCO.2009.27.9158","article-title":"Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial","volume":"28","author":"Harousseau","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.blre.2015.06.001_bb0215","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.blre.2015.06.001_bb0220","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood-2009-05-222539","article-title":"A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma","volume":"115","author":"Lokhorst","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2015.06.001_bb0225","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3324\/haematol.2011.043372","article-title":"Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC myeloma IX randomized trial results","volume":"97","author":"Morgan","year":"2012","journal-title":"Haematologica"},{"issue":"22","key":"10.1016\/j.blre.2015.06.001_bb0230","doi-asserted-by":"crossref","first-page":"5752","DOI":"10.1182\/blood-2011-05-355081","article-title":"Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma","volume":"118","author":"Moreau","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2015.06.001_bb0235","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/j.1365-2141.2008.06997.x","article-title":"Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up","volume":"141","author":"Popat","year":"2008","journal-title":"Br J Haematol"},{"issue":"30","key":"10.1016\/j.blre.2015.06.001_bb0240","doi-asserted-by":"crossref","first-page":"5015","DOI":"10.1200\/JCO.2008.19.5370","article-title":"Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma","volume":"27","author":"Jakubowiak","year":"2009","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.blre.2015.06.001_bb0245","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.3324\/haematol.2012.067793","article-title":"Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma","volume":"97","author":"Arnulf","year":"2012","journal-title":"Haematologica"},{"issue":"21","key":"10.1016\/j.blre.2015.06.001_bb0250","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1182\/blood.V122.21.404.404","article-title":"Bortezomib induction and maintenance treatment improves survival in patients with newly diagnosed multiple myeloma:extended follow-up of the HOVON-65\/GMMG-HD4 trial","volume":"122","author":"Sonneveld","year":"2013","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2015.06.001_bb0255","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/leu.2009.26","article-title":"Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial","volume":"23","author":"Reeder","year":"2009","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.blre.2015.06.001_bb0260","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.blre.2015.06.001_bb0265","doi-asserted-by":"crossref","first-page":"4375","DOI":"10.1182\/blood-2011-11-395749","article-title":"Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma","volume":"119","author":"Kumar","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2015.06.001_bb0270","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/bjh.12946","article-title":"Bortezomib-cyclophosphamide-dexamethasone (VCD) versus bortezomib-thalidomide-dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis","volume":"166","author":"Leiba","year":"2014","journal-title":"Br J Haematol"},{"issue":"21","key":"10.1016\/j.blre.2015.06.001_bb0275","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1182\/blood.V124.21.197.197","article-title":"Superior Efficacy of VTD over VCD As Induction Therapy for Autotransplantation-Eligible, Newly Diagnosed, Myeloma Patients","volume":"124","author":"Cavo","year":"2014","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.blre.2015.06.001_bb0280","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1200\/JCO.2013.54.8164","volume":"32","author":"Roussel","year":"2014","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.blre.2015.06.001_bb0285","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2012.48.4626","article-title":"Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials","volume":"31","author":"Sonneveld","year":"2013","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.blre.2015.06.001_bb0290","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1182\/blood.V122.21.688.688","article-title":"Dose escalation phase 2 trial of carfilzomib combined with thalidomide and low-dose dexamethason in newly diagnosed, transplant eligible patients with multiple myeloma. A trial Of The European Myeloma Network","volume":"122","author":"Asselberg-Hacker","year":"2013","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2015.06.001_bb0295","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1182\/blood-2012-04-422683","article-title":"A phase 1\/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma","volume":"120","author":"Jakubowiak","year":"2012","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.blre.2015.06.001_bb0300","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1182\/blood.V122.21.3179.3179","article-title":"A phase I\/II trial of cyclophosphamide, Carfilzomib, thalidomide and dexamethasone (CYCLONE) In patients with newly diagnosed multiple myeloma: final results Of MTD Expansion Cohort","volume":"122","author":"Reeder","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2015.06.001_bb0305","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1200\/JCO.2011.39.5137","article-title":"Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma","volume":"31","author":"Ludwig","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.blre.2015.06.001_bb0310","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1182\/blood-2011-02-334755","article-title":"Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1\/2 Multiple Myeloma Research Consortium trial","volume":"118","author":"Jakubowiak","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2015.06.001_bb0315","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome","volume":"335","author":"Attal","year":"1996","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.blre.2015.06.001_bb0320","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.blre.2015.06.001_bb0325","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1182\/blood-2005-03-1301","article-title":"High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA","volume":"106","author":"Blade","year":"2005","journal-title":"Blood"},{"issue":"36","key":"10.1016\/j.blre.2015.06.001_bb0330","doi-asserted-by":"crossref","first-page":"9227","DOI":"10.1200\/JCO.2005.03.0551","article-title":"High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65years: long-term results of a randomized control trial from the Group Myelome-Autogreffe","volume":"23","author":"Fermand","year":"2005","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.blre.2015.06.001_bb0335","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1200\/JCO.2005.04.5807","article-title":"Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321","volume":"24","author":"Barlogie","year":"2006","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.blre.2015.06.001_bb0340","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.blre.2015.06.001_bb0345","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/sj.bmt.1701763","article-title":"Melphalan 220mg\/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma","volume":"23","author":"Moreau","year":"1999","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.blre.2015.06.001_bb0350","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1182\/blood.V99.3.731","volume":"99","author":"Moreau","year":"2002","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.blre.2015.06.001_bb0355","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.bbmt.2007.08.002","article-title":"Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients","volume":"13","author":"Carreras","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.blre.2015.06.001_bb0360","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.3324\/haematol.2010.028027","article-title":"Busulfan 12mg\/kg plus melphalan 140mg\/m2 versus melphalan 200mg\/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA\/GEM2000 study","volume":"95","author":"Lahuerta","year":"2010","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.blre.2015.06.001_bb0365","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1080\/10428190802630170","article-title":"Single daily dose of intravenous busulfan and melphalan as a conditioning regimen for patients with multiple myeloma undergoing autologous stem cell transplantation: a phase II trial","volume":"50","author":"Blanes","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.blre.2015.06.001_bb0370","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/blood-2009-06-229658","article-title":"Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM)","volume":"115","author":"Roussel","year":"2010","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.blre.2015.06.001_bb0375","doi-asserted-by":"crossref","first-page":"5079","DOI":"10.1158\/1078-0432.CCR-10-1662","article-title":"A phase I\/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study","volume":"16","author":"Lonial","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"21","key":"10.1016\/j.blre.2015.06.001_bb0380","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1182\/blood.V122.21.3357.3357","article-title":"Busulfan\/melphalan\/bortezomib (Bu\u2013Mel\u2013Vel) vs. high dose melphalan as conditioning regimen for autologous hematopoietic cell transplantation in multiple myeloma (MM)","volume":"122","author":"Hari","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2015.06.001_bb0385","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.bbmt.2013.02.013","article-title":"A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma","volume":"19","author":"Mark","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"26","key":"10.1016\/j.blre.2015.06.001_bb0390","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa032290","article-title":"Single versus double autologous stem-cell transplantation for multiple myeloma","volume":"349","author":"Attal","year":"2003","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.blre.2015.06.001_bb0395","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1200\/JCO.2006.10.2509","article-title":"Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study","volume":"25","author":"Cavo","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2015.06.001_bb0400","series-title":"First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies","first-page":"Cd004626","volume":"10","author":"Naumann-Winter","year":"2012"},{"issue":"24","key":"10.1016\/j.blre.2015.06.001_bb0405","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","article-title":"Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/ GMMG-HD4 trial","volume":"30","author":"Sonneveld","year":"2012","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.blre.2015.06.001_bb0410","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1182\/blood.V122.21.767.767","article-title":"Double vs single autologous stem cell transplantation after bortezomib-based induction regimens for multiple myeloma: an integrated analysis of patient-level data from Phase European III Studies","volume":"122","author":"Salwender","year":"2013","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.blre.2015.06.001_bb0415","doi-asserted-by":"crossref","first-page":"4647","DOI":"10.1182\/blood-2012-11-464503","article-title":"Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial","volume":"121","author":"Mellqvist","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2015.06.001_bb0420","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2012-02-408898","article-title":"Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma","volume":"120","author":"Cavo","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2015.06.001_bb0425","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/leu.2014.219","article-title":"Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival","volume":"29","author":"Ferrero","year":"2015","journal-title":"Leukemia"},{"issue":"19","key":"10.1016\/j.blre.2015.06.001_bb0430","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.blre.2015.06.001_bb0435","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1182\/blood-2013-03-492678","article-title":"Implications of continued response after autologous stem cell transplantation for multiple myeloma","volume":"122","author":"Gonsalves","year":"2013","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2015.06.001_bb0440","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1182\/blood-2006-05-022962","article-title":"Maintenance therapy with thalidomide improves survival in patients with multiple myeloma","volume":"108","author":"Attal","year":"2006","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2015.06.001_bb0445","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1200\/JCO.2005.04.5807","article-title":"Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321","volume":"24","author":"Barlogie","year":"2006","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.blre.2015.06.001_bb0450","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/ajh.23274","article-title":"Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma","volume":"87","author":"Maiolino","year":"2012","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.blre.2015.06.001_bb0455","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2011-06-357038","article-title":"The role of maintenance thalidomide therapy in multiple myeloma: MRC myeloma IX results and meta-analysis","volume":"119","author":"Morgan","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2015.06.001_bb0460","series-title":"Maintenance therapy after stem-cell transplantation for multiple myeloma with bortezomib\/thalidomide vs. thalidomide vs. alfa2b-interferon: final results of a phase III Pethema\/GEM Randomized Trial","first-page":"334","volume":"120","author":"Rosinnol","year":"2012"},{"issue":"11","key":"10.1016\/j.blre.2015.06.001_bb0465","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1200\/JCO.2008.18.8573","article-title":"Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure","volume":"27","author":"Spencer","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.blre.2015.06.001_bb0470","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1182\/blood-2012-09-451872","article-title":"A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial","volume":"121","author":"Stewart","year":"2013","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.blre.2015.06.001_bb0475","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1182\/blood-2008-03-145235","article-title":"Thalidomide arm of total therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities","volume":"112","author":"Barlogie","year":"2008","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.blre.2015.06.001_bb0480","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1182\/blood.V122.21.3332.3332","article-title":"Thalidomide combined with high dose melphalan improves event free and overall survival in patients with newly diagnosed multiple myeloma: extended follow-up of the HOVON-50 Trial","volume":"122","author":"Lokhorst","year":"2013","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.blre.2015.06.001_bb0485","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.blre.2015.06.001_bb0490","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1182\/blood.V122.21.2089.2089","article-title":"Maintenance therapy with lenalidomide significantly improved survival of yong newly diagnosed multiple myeloma patients","volume":"122","author":"Gay","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2015.06.001_bb0495","series-title":"Maintenance treatment with lenalidomide after transplantation for MYELOMA: final analysis of the IFM 2005-02","first-page":"310","volume":"116","author":"Attal","year":"2010"},{"issue":"21","key":"10.1016\/j.blre.2015.06.001_bb0500","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1182\/blood.V122.21.406.406","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma: follow-up analysis of the IFM 2005-02 Trial","volume":"122","author":"Attal","year":"2013","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.blre.2015.06.001_bb0505","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1182\/blood.V122.21.2089.2089","article-title":"Maintenance therapy with lenalidomide significantly improved survival of yong newly diagnosed multiple myeloma patients","volume":"122","author":"Gay","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2015.06.001_bb0510","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/cyto.b.20512","article-title":"Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders","volume":"78","author":"Paiva","year":"2010","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.blre.2015.06.001_bb0515","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1182\/blood-2014-01-550020","article-title":"Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma","volume":"123","author":"Martinez-Lopez","year":"2014","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.blre.2015.06.001_bb0520","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1182\/blood.V122.21.1936.1936","article-title":"PET\/CT is a useful tool for both refining the definition of complete response (CR) in multiple myeloma (MM) and detecting otherwise unrevealed progression during the follow-up of the disease: a single centre experience on 282 patients","volume":"122","author":"Zamagni","year":"2013","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.blre.2015.06.001_bb0525","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S1470-2045(14)71125-8","article-title":"Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1\/2 study","volume":"15","author":"Kumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"21","key":"10.1016\/j.blre.2015.06.001_bb0530","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1182\/blood.V124.21.82.82","article-title":"Long-term ixazomib maintenance is tolerable and improves depth of response following ixazomib\u2013lenalidomide\u2013dexamethasone induction in patients (Pts) with previously untreated multiple myeloma (MM): phase 2 study results","volume":"124","author":"Kumar","year":"2014","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.blre.2015.06.001_bb0535","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJMe1202819","article-title":"Lenalidomide in myeloma\u2014a high-maintenance friend","volume":"366","author":"Badros","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.blre.2015.06.001_bb0540","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3324\/haematol.2013.099358","article-title":"European myeloma network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma","volume":"99","author":"Engelhardt","year":"2014","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.blre.2015.06.001_bb0545","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1001\/jama.1969.03160090040009","article-title":"Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens","volume":"208","author":"Alexanian","year":"1969","journal-title":"JAMA"},{"issue":"9513","key":"10.1016\/j.blre.2015.06.001_bb0550","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","article-title":"Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial","volume":"367","author":"Palumbo","year":"2006","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.blre.2015.06.001_bb0555","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1200\/JCO.2008.21.0948","article-title":"Efficacy of melphalan and prednisone plus thalidomide in patients older than 75years with newly diagnosed multiple myeloma: IFM 01\/01 trial","volume":"27","author":"Hulin","year":"2009","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.blre.2015.06.001_bb0560","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1200\/JCO.2009.26.1610","article-title":"Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study","volume":"28","author":"Wijermans","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.blre.2015.06.001_bb0565","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1182\/blood-2009-08-237974","article-title":"Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma","volume":"116","author":"Waage","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2015.06.001_bb0570","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1600-0609.2010.01524.x","article-title":"Addition of thalidomide to oral melphalan\/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group","volume":"86","author":"Beksac","year":"2011","journal-title":"Eur J Haematol"},{"issue":"19","key":"10.1016\/j.blre.2015.06.001_bb0575","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma","volume":"366","author":"Palumbo","year":"2012","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.blre.2015.06.001_bb0580","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1182\/blood.V124.21.179.179","article-title":"Randomized phase III trial in non-transplant eligible patients with newly diagnosed symptomatic multiple myeloma comparing melphalan-prednisone-thalidomide followed by thalidomide maintenance (MPT-T) versus melphalan-prednisone\u2013lenalidomide followed by M\u2026.","volume":"124","author":"Zweegman","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2015.06.001_bb0585","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1200\/JCO.2012.41.6180","article-title":"Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma","volume":"31","author":"San Miguel","year":"2013","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.blre.2015.06.001_bb0590","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S1470-2045(10)70187-X","volume":"11","author":"Mateos","year":"2010","journal-title":"Lancet Oncol"},{"issue":"34","key":"10.1016\/j.blre.2015.06.001_bb0595","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1200\/JCO.2010.29.8216","article-title":"Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib\u2013melphalan\u2013prednisone for initial treatment of multiple myeloma: a randomized controlled trial","volume":"28","author":"Palumbo","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.blre.2015.06.001_bb0600","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1182\/blood-2011-02-338665","article-title":"Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation","volume":"118","author":"Morgan","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2015.06.001_bb0605","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00432-005-0074-4","volume":"132","author":"Ponisch","year":"2006","journal-title":"J Cancer Res Clin Oncol"},{"issue":"15","key":"10.1016\/j.blre.2015.06.001_bb0610","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1182\/blood-2008-07-169565","article-title":"Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma","volume":"113","author":"Ludwig","year":"2009","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.blre.2015.06.001_bb0615","doi-asserted-by":"crossref","first-page":"5838","DOI":"10.1182\/blood-2010-08-303487","article-title":"Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)","volume":"116","author":"Zonder","year":"2010","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.blre.2015.06.001_bb0620","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1182\/blood.V124.21.178.178","article-title":"Comparison of sequential vs alternating administration of bortezomib, melphalan, prednisone (VMP) and lenalidomide plus dexamethasone (Rd) in elderly pts with newly diagnosed multiple myeloma (MM) patients: GEM2010MAS65 Trial","volume":"124","author":"Mateos","year":"2014","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.blre.2015.06.001_bb0625","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1182\/blood-2008-04-149427","article-title":"Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial","volume":"112","author":"Palumbo","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2015.06.001_bb0630","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2011-06-357038","article-title":"The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis","volume":"119","author":"Morgan","year":"2012","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.blre.2015.06.001_bb0635","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1182\/blood-2012-05-427815","article-title":"Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial","volume":"120","author":"Mateos","year":"2012","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2015.06.001_bb0640","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1200\/JCO.2013.52.0023","article-title":"Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival","volume":"32","author":"Palumbo","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2015.06.001_bb0645","doi-asserted-by":"crossref","first-page":"980","DOI":"10.3324\/haematol.2012.075051","article-title":"Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials","volume":"98","author":"Bringhen","year":"2013","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.blre.2015.06.001_bb0650","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2015.06.001_bb0655","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/S0145-2126(12)70007-3","article-title":"How to maintain patients on long-term therapy: understanding the profile and kinetics of adverse events","volume":"36","author":"Mateos","year":"2012","journal-title":"Leuk Res"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X15000430?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X15000430?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,9]],"date-time":"2024-06-09T14:04:15Z","timestamp":1717941855000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X15000430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":131,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S0268960X15000430"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2015.06.001","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment for patients with newly diagnosed multiple myeloma in 2015","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2015.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}